Search This Blog

Thursday, August 8, 2019

Nektar Therapeutics EPS beats by $0.17, misses on revenue

Nektar Therapeutics (NASDAQ:NKTR): Q2 GAAP EPS of -$0.63 beats by $0.17.
Revenue of $23.3M (-97.9% Y/Y) misses by $3.35M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)